0.00Open0.30Pre Close0 Volume2 Open Interest21.00Strike Price0.00Turnover115.34%IV11.55%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.30Extrinsic Value100Contract SizeAmericanOptions Type0.2345Delta0.1323Gamma63.65Leverage Ratio-0.0902Theta0.0005Rho14.93Eff Leverage0.0062Vega
Rigel Pharmaceuticals Stock Discussion
whoa! some Dip
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA has granted Fast Track designation to R289 for treating patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in a Phase 1b study. The Fast Track designation may provide benefits including more freque...
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Let's break 30.+
27.+
Let's Get 30.+
No comment yet